Aemetis, Inc. (NASDAQ:AMTX) belongs to Basic Materials sector. Its net profit margin is -5.00% and weekly performance is -2.19%. On last trading day company shares ended up $3.57. Aemetis, Inc. (NASDAQ:AMTX) distance from 50-day simple moving average (SMA50) is -16.87%. Zacks reiterated their hold rating on shares of Aemetis (NASDAQ:AMTX) in a research note released on Friday morning.
Celsion Corp. (NASDAQ:CLSN) shares advanced 4.55% in last trading session and ended the day at $2.30. CLSN return on assets is -38.80%. Celsion Corp. (NASDAQ:CLSN) quarterly performance is -11.54%. Celsion Corporation (NASDAQ:CLSN) reported encouraging interim data from its ongoing phase II DIGNITY study on ThermoDox for recurrent chest wall (RCW) breast cancer. The study is evaluating ThermoDox in combination with mild hyperthermia.
On 10 July, Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares advanced 4.74% and was closed at $10.82. NWBO EPS growth in last 5 year was 23.90%. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) year to date (YTD) performance is 102.24%.
Aerohive Networks, Inc. (NYSE:HIVE) ended the last trading day at $7.11. Company weekly volatility is calculated as 4.48% and price to cash ratio as 3.58. Aerohive Networks, Inc. (NYSE:HIVE) showed a weekly performance of 3.95%. The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Aerohive Networks Inc. (NYSE:HIVE) common stock pursuant and/or traceable to the Company’s March 27, 2014 Initial Public Offering (“IPO”). The lawsuit seeks to recover damages for Aerohive investors under the federal securities laws.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares advanced 3.81% in last trading session and ended the day at $116.94. RARE return on assets is -29.10%. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) quarterly performance is 88.19%. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced positive interim data from the first 12 patients in the ongoing pediatric Phase 2 study for its recombinant human monoclonal antibody KRN23 against fibroblast growth factor 23 (FGF23) for the treatment of X-linked hypophosphatemia (XLH). An improvement in mean rickets score was observed after 40 weeks of treatment with investigational KRN23 in these patients.